Glenmark's commitment to providing affordable and effective solutions highlights its role as a leader in diabetes care. As Zita DM becomes a part of ... Oct 19
If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the EU suffering from chronic kidney disease... Jun 28
Farxiga could become the first SGLT2 inhibitor approved to treat patients with chronic kidney disease, with and without type-2 diabetes... Jan 06
For roxadustat, more than 40 abstracts present safety and efficacy outcomes in anaemia of chronic kidney disease ... Oct 20
If approved, Forxiga would become the first SGLT2 inhibitor indicated for heart failure with reduced ejection fraction in patients with and without type-2 diabetes... Oct 19
Zydus Healthcare Limited announced that it is launching the anti-diabetic Dapagliflozin tablets in India upon its patent expiry under the brand name ‘Dapaglyn’... Oct 05
Early-stage human trial data on a vaccine being developed by AstraZeneca and Oxford University will be published on July 20. ... Jul 17
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. ... Apr 30
Earlier in April 2019, Glenmark received regulatory approval for Remogliflozin etabonate in India and became the first company in the world to launch Remogliflozin with ... Sep 14
-Advertisements-
Thursday, May 02, 2024
.jpeg)
